{"name":"Caris Life Sciences","slug":"caris","ticker":"PRIVATE","exchange":"Private","domain":"carislifesciences.com","description":"Caris Life Sciences is a precision medicine and diagnostics company that provides molecular profiling and genomic testing services. The company focuses on developing and commercializing innovative diagnostic tests for various types of cancer. Caris Life Sciences has established itself as a leader in the precision medicine and diagnostics market, with a strong presence in the US and globally. The company's tests are used by oncologists and other healthcare professionals to guide treatment decisions for patients with cancer.","hq":"Irving, TX","founded":0,"employees":"","ceo":"David D. Halbert","sector":"Precision Medicine & Diagnostics","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"~$7.8B (last private valuation)","metrics":{"revenue":812033000,"revenueGrowth":97,"grossMargin":0,"rdSpend":101584000,"netIncome":-68088000,"cash":1125663000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Caris Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Caris Life Sciences reported its financial results for the fourth quarter and full year 2023, with revenue increasing by 15% year-over-year.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"Caris Life Sciences Partners with Foundation Medicine to Enhance Precision Medicine Capabilities","summary":"Caris Life Sciences partnered with Foundation Medicine to expand its precision medicine capabilities and improve patient outcomes.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-04-02","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-03","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxOOGVGa29XMHZnZlp1bmlNdlJaaXJZYnE0bXVHX2U3dkxscER0bFd1U1lfcld0Z0dUM1R2bmd5cnpPdFNDSl8yd180RWNac25nb19vTlBIZTJTREluSFFnVUZaa2ZuTnNHMW9hSHZUdGxnNnV4UFRPRkU0MEU2bmpraG52M094VGFZYVVrWFRJQ3FuX215bHZILTVwN0ViREI5dWprV1c0UHFZUE03V3p0QnR2bVBxbVJHYUFndFJ6Rm1UOXU3Z3lkdk5YNFVlV2FicUwzcGd5eTVBb01r?oc=5","date":"2026-01-12","type":"earnings","source":"Morningstar","summary":"Caris Life Sciences Announces Preliminary Fourth Quarter and Full Year 2025 Results - Morningstar","headline":"Caris Life Sciences Announces Preliminary Fourth Quarter and Full Year 2025 Results","sentiment":"neutral"},{"date":"2026-01-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxONENhUTM3a2xqbjZqaEhSbWxRSWJ3eFItdzNna2dLcTFkV3ItSjY0ZFNLTkVySm9STlFFSzVoR1FBUGdoTkhjMkNnRG1mZFBZR1Q1TndlVklOLTJlYkFzNTN1UnVmMjZVZTYyaE1NZjFsSmVnaVlrSkE1eFZUSzhjcFBGcU12MGRjN3lCSkx1TVIySGdQR3kzYjl5dlRsdXRkR3JZS0RTRmVoUVNYWmh1TQ?oc=5","date":"2025-12-19","type":"deal","source":"Drug Discovery News","summary":"Weekly Rundown: Genentech partners with Caris Life Sciences in $1.1B deal - Drug Discovery News","headline":"Weekly Rundown: Genentech partners with Caris Life Sciences in $1.1B deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxNVlUwRExUekl6T2I2d29ESDBtVE5ZYUZ6c1ppUkdOanN0VktZRm9fYVl6RVhRQmZVcEFjU2tscGZnQjhwQ0xxOWo1OU0yUko2RkIzbTd4Uy1fME1RcjdOcmREUWdMRllmSHBDQ3JyQ1Zuemg3MUd6YnhtNFNTajVJaGhwZXg2aHlIZE40ZExvYlBaeXktcnh6R0VzR3FteU5EMWhRSnRBV2RTR3loYVJkY2V0LS0zWXQ0eG83bGFwdWZxRVE5cGdHU21LYkhUQ0E?oc=5","date":"2025-11-05","type":"earnings","source":"Investing.com","summary":"Earnings call transcript: Caris Life Sciences sees 113% revenue surge in Q3 2025 - Investing.com","headline":"Earnings call transcript: Caris Life Sciences sees 113% revenue surge in Q3 2025","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE1xTmgtUEQtZVNRNXNjSWI1eWpVTHVxR0hKSG9hVHhkMkVaZjhPYVp5eEppemlmOFpETFlUTjdDWUM2NldkTnk1Z1lfeEJGTlBQYlVNbUlrcFFMa1ZT?oc=5","date":"2025-09-18","type":"trial","source":"MLQ.ai","summary":"Tempus AI (TEM): At the Crossroads of Diagnostics and Data - MLQ.ai","headline":"Tempus AI (TEM): At the Crossroads of Diagnostics and Data","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxQN2dRcGItRThheGZBdFpWZjVNbzRjcDJmOGlOTk1BQmxSMVM1OVA1STdOM0REclhnYzE0TGhocmw0V1FZRHdFVkNOYTVEZTVkRTZ6QWNaTEpFSG13MVdFZlhhY3FxUHBHMWpWYU9xREFpYWRmWUxuQUhkUlB6YVNEeHZNTmhqQkFvTnlXMWFKUjk0dHpqYVE?oc=5","date":"2025-08-15","type":"pipeline","source":"Crunchbase News","summary":"Biotech Isn’t Partaking In The IPO Rebound - Crunchbase News","headline":"Biotech Isn’t Partaking In The IPO Rebound","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNMXFGU2R2bFhQLU82ZnA1UktSSjd2b3d0cHcwQjJHTEN0VWw4ajZ3Zm16X25JTU9aV01QMmpWOHNyVFF5Ty03b1JaZmVTMnNra0VKZTBNWDZHaml2WDJSVFlLTkhNc1A5RFVIZm5oeEZldDJRbzh3d1pxNzJOSGNKSzhzT2xYYUVYdmNmVlZiSzcwSzlJWXUzbVRBdGtGc1BBZ0lMYnJHV0szZTVycWc?oc=5","date":"2025-06-18","type":"pipeline","source":"Forbes","summary":"Founder Of Biotech Firm Caris Life Sciences Becomes A Billionaire After IPO - Forbes","headline":"Founder Of Biotech Firm Caris Life Sciences Becomes A Billionaire After IPO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxObTFkM2FnczRSZ2pSSExFZS1aNWJCUzlCOXRlcDUxVGxOMWVOOUpaV2ppV1dHSUFjMEQ1QlNteTdmc1l0ZEVUVjVWNXI2M2NQbVVZVjlFald6aFBqWVpRU1hNOW1tOTR4Nm9jZDRVTnRZYTBtU0ZRQjhBWDNrVGh3a3NpZUFsTDEy?oc=5","date":"2025-06-17","type":"pipeline","source":"pharmaphorum","summary":"Caris swells its planned IPO, seeking $5.7bn valuation - pharmaphorum","headline":"Caris swells its planned IPO, seeking $5.7bn valuation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxONmZmSE9iaHZEaGJtMVRtcVp2VlNMVWlHQkx3WlFSek9OMS1tMFF5Q1FRc3JLUUJDaWVXVVRTcmJrSV9MR0pZUDh0bGhfYy1XTmlQWVhIUTlzMXZCdS1mVVd6ZGJSeWZhaWFtNzQyMlJPZUY5N0NfVDZjcnQtUlk5eEF1VGtwYVFFeUk5emFvWXZYbEUtcFNpcTFWRzZudw?oc=5","date":"2025-06-09","type":"pipeline","source":"Fierce Biotech","summary":"Cancer tester Caris Life Sciences to go public in $400M Nasdaq IPO - Fierce Biotech","headline":"Cancer tester Caris Life Sciences to go public in $400M Nasdaq IPO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQcHlFZ1BoanIxbG5IYWpwOF9XWm1Gd0huSmZCM2kwTEMydmt0XzBObkdUeXRiTllDdHhRMXF3WEZjWEZIWUp1a2xwQWlnV1d0XzVFY05qLUllX3p2RDRxNmhpdzFESGhEa3NOVVRnZzF2Y0FIa3dpQzVHTmYzd1BGcHBVQmZXSWU4eEltbTZybw?oc=5","date":"2025-05-23","type":"pipeline","source":"SEC.gov","summary":"tm2415719-14_s1 - none - 45.5939491s - SEC.gov","headline":"tm2415719-14_s1 - none - 45.5939491s","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFBrZmpyZjd5dzc5LW9EWld4ZUx1QmtjOEdCNzJtZHBGMzRNRUdsS05MYzJsU05Sb0JyZ3JadHJKcHAxZ1FiVm1yOWQzclV1RXlRMVpQRzFPT3M3d19rZFI5d3BEelpqWER6Wkl2dzlB?oc=5","date":"2023-11-29","type":"pipeline","source":"drugdiscoverytrends.com","summary":"Top 50 biotechs of 2023: Molecular science emerges as a focus - drugdiscoverytrends.com","headline":"Top 50 biotechs of 2023: Molecular science emerges as a focus","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wJBVV95cUxPMjdHcDdGa3VsRE9GTTdDdlhpREJEeEVMcmdXLVR5Ti12S3VqOE5SQ3FZOC1TTFh5X19OUnE4a1FDbkdRT0pSUFRBdFh0VnFTdVNFYTd3TWFGV0Zidng0bnhNbDJmME1meE9Gc0x2THFxazBURjNTSzJPeVRlNTJMa0VTVTVRWlRKb3MybFJTcFJmUWh5MWlyUTN0M1RkLUZxNF9lRnloQ3Radlc1ZmpZUVZ6SE9xM2JGSmM5bkMxOUlvMFdUbTVrYjJ0ZGxpX3lST0NRMUw5SVZRd09FZVh1a3F6bDhCY1NwVEVQbm1nOHpIeS1wdGRIXzBScDFGRzN1QmoyZ0NLNkhRdFA0QUR5ZnZXMHkzTkNJQmtkMlhoN2dJM3U5SVhidjAtSjY2ajUwWm1oVDUyb0pCV2hrN1dveG9KdFlGMVNIOTNQY2k0b0VCX00?oc=5","date":"2021-10-14","type":"deal","source":"PR Newswire","summary":"Caris Life Sciences and Ono Pharmaceutical Announce Strategic Collaboration Leveraging Caris' Novel, Blood-Based cNAS Molecular Profiling Assay Across Several Ono Clinical Studies - PR Newswire","headline":"Caris Life Sciences and Ono Pharmaceutical Announce Strategic Collaboration Leveraging Caris' Novel, Blood-Based cNAS Mo","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Foundation Medicine","Invitae Corporation","Exact Sciences Corporation"],"therapeuticFocus":["Oncology"],"financials":{"source":"sec_edgar+yahoo","revenue":812033000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":812033000,"period":"2025-12-31"},{"value":412260000,"period":"2024-12-31"},{"value":306128000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":101584000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-68088000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":1125663000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}